Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-03 02:01 UTC

BIOMED PULSE

September 3, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 60 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the DRC — and it is still accelerating. [1] Mood: deeply concerning on the outbreak front; longevity science offers cautious optimism with new senescence-targeting biomaterial strategies emerging from the literature. [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA: RECORD-BREAKING OUTBREAK

  • As of August 28, 2026, the Bundibugyo virus disease (BVD) outbreak has spread to 60 health zones, up from 54 at the previous report, spanning six of the DRC's 26 provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • WHO's August 14 DON described the outbreak as in a phase of "intense transmission," the largest Ebola outbreak ever reported in DRC, and expanding faster than any previous Ebola outbreak. [4]
  • As of July 15, 2026, cumulative confirmed cases stood at 2,124 with 828 deaths; the trajectory has continued sharply upward through late August. [5]
  • Cross-border transmission to Uganda has been confirmed and remains an ongoing concern per multiple WHO Disease Outbreak News reports dating from May through July 2026. [6] [5]
  • CDC mobilized an international Ebola response starting May 17, 2026, and expanded airport entry screening to Washington-Dulles and Atlanta to catch travelers from affected regions. [7] [8]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth DON (July 2, 2026) confirmed the outbreak involves Andes hantavirus (ANDV) linked to passengers and crew aboard the cruise ship M/V Hondius, which first reported severe respiratory illness cases on May 2, 2026. [9]
  • As of the May 28 DON (fourth report), additional confirmed cases had been identified beyond the initial seven (two lab-confirmed, five suspected) reported when the ship carried 147 passengers and crew. [10]
  • CDC's Emergency Operations Center provided ongoing response updates through late June 2026, noting risk to the U.S. general public remained extremely low.

MEASLES — BANGLADESH

  • WHO notified on April 23, 2026, of a nationwide measles surge in Bangladesh affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.
  • This follows a global surge in which measles infected 10.3 million people worldwide in 2023, per CDC data released in late 2024.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO's April 10, 2026, DON reported a single human case in an adult male returning from Senegal; next-generation sequencing confirmed influenza A(H9N2).
  • No sustained human-to-human transmission was reported; this is a surveillance signal worth watching given the H5N1 trajectory in the United States in prior months.

WEST NILE VIRUS — UNITED STATES

  • CDC flagged an early and record-setting West Nile virus season as of July 1, 2026, urging mosquito bite prevention over the Independence Day holiday weekend and beyond.

CYCLOSPORA — UNITED STATES

  • CDC confirmed on July 17, 2026, that shredded iceberg lettuce served at Taco Bell locations was the source of a Cyclospora outbreak affecting five states, with 1,644 people sickened.
  • The outbreak subsequently expanded to four additional states as of July 24, 2026.

SALMONELLA — MULTIPLE ACTIVE OUTBREAKS, UNITED STATES

  • A Salmonella outbreak linked to jalapeños was posted as a food safety alert by CDC on August 5, 2026.
  • A separate multistate outbreak linked to alfalfa sprouts involves both Salmonella and E. coli simultaneously, with a recall issued as of August 21, 2026.

E. COLI — FROZEN BLUEBERRIES, UNITED STATES

  • CDC warned on July 7, 2026, of an E. coli outbreak linked to frozen blueberries, with a product recall in effect; consumers advised not to eat the recalled product.

NIPAH VIRUS — INDIA

  • WHO's June 25, 2026, DON reported one laboratory-confirmed Nipah virus (NiV) case in an adult male in Kozhikode district, Kerala State, India, with symptom onset May 30 and hospitalization June 10, 2026; neurological presentation was noted.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported a total of 79 human yellow fever infections, continuing elevated transmission that carried over from 2025 increases in the Americas, per WHO.

🧬 LONGEVITY & AGING

SENESCENCE AND INTERVERTEBRAL DISC DEGENERATION

  • A Biomaterials study (published July 14, 2026) describes engineered extracellular vesicles loaded into injectable hydrogel microspheres that selectively target senescent cells in spinal disc tissue and also suppress ferroptosis (an iron-driven form of cell death) in nucleus pulposus cells, potentially offering a two-pronged approach to disc degeneration. [2]
  • A separate Bioactive Materials study (published July 31, 2026) used a dual antioxidant-plus-epigenetic drug combination to break the self-reinforcing cycle of cellular senescence in osteoarthritic joints, demonstrating that targeting multiple aging pathways simultaneously can outperform single-agent senolytics. [3]

EGFR AND BONE HEALING IN AGING

  • A Bioactive Materials study published August 4, 2026, found that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is strongly associated with impaired fracture healing in aged mice — identifying EGFR signaling as a potential therapeutic target for the estimated millions of older adults who suffer slow or non-healing fractures annually.

CHOLESTEROL AND AGE-RELATED BONE DEFECTS

  • Researchers published August 20, 2026 in Bioactive Materials described a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis in bone tissue, significantly promoting repair of age-related bone defects in preclinical models — an early but notable convergence of mRNA delivery technology and bone aging biology.

TESTOSTERONE, LONGEVITY, AND REPRODUCTIVE FITNESS

  • A Mendelian randomization study published August 17, 2026, in Aging Male found that testosterone produces measurable trade-offs between longevity and reproductive fitness — higher testosterone associated with reproductive advantages but potentially shorter lifespan — using genetically predicted testosterone levels to reduce confounding.
  • A companion international expert consensus paper (Aging Male, August 26, 2026) from a 12-author global panel including T.H. Jones, M. Khera, A.M. Traish, and M. Zitzmann outlined updated primary care guidance for managing testosterone deficiency, emphasizing individualized risk-benefit assessment.

CALORIE RESTRICTION AND LIFESPAN — SCALLOP COMPARATIVE GENOMICS

  • A transcriptomics study published August 10, 2026, in Comparative Biochemistry and Physiology compared two Argopecten scallop species with distinct natural lifespans under calorie restriction, revealing species-specific adaptive transcriptomic strategies that illuminate how different organisms use diet restriction to extend lifespan — findings with implications for understanding the molecular basis of longevity variation.

HEAT TOLERANCE AND AGING POPULATIONS — LANCET PLANETARY HEALTH

  • Modeling published in Lancet Planetary Health projects that a warming climate will cause a rapidly growing proportion of the world's aging population to exceed human physiological heat tolerance thresholds, with older adults disproportionately at risk due to reduced thermoregulatory capacity.

SLEEP DURATION AND HYPERTENSION IN OLDER ADULTS

  • A cross-sectional study published August 16, 2026, in Blood Pressure found a significant association between sleep duration and hypertension in older adults, reinforcing that sleep management is a modifiable longevity-relevant factor in aging populations.

OSTEOARTHRITIS IMMUNE DYSREGULATION

  • A Journal of Translational Autoimmunity review (August 20, 2026) catalogued immune dysregulation mechanisms in osteoarthritis — including macrophage polarization, complement activation, and T-cell infiltration — and identified emerging biomarkers and therapeutic opportunities that could reframe OA as an immunological disease amenable to biologic intervention.

DEPRESCRIBING IN OLDER ADULTS — CALL FOR RATIONALE-FIRST FRAMEWORK

  • Two linked Lancet Healthy Longevity commentaries (Hwang, Boockvar, Steinman; and Van der Linden) argue that deprescribing trials in older adults currently lack a systematic rationale-first framework for choosing trial design, urging the field to define the mechanism and goal of deprescribing before selecting methodology — a practical point for clinicians managing polypharmacy in aging patients.

💊 NEW CURES & APPROVALS

IMAAVY (NIPOCALIMAB-AAHU) — JANSSEN BIOTECH, SUPPLEMENTAL APPROVAL

  • Janssen Biotech received a supplemental approval (SUPPL AP) for IMAAVY, whose active ingredient nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker that reduces pathogenic IgG antibody levels — a mechanism relevant to autoimmune and alloimmune diseases; this supplemental action expands its regulatory profile.

ZIIHERA (ZANIDATAMAB-HRII) — JAZZ PHARMACEUTICALS, SUPPLEMENTAL APPROVAL

  • Jazz Pharmaceuticals received a supplemental approval for ZIIHERA (zanidatamab-hrii), a bispecific HER2-targeting antibody; supplemental actions typically reflect new indications or population expansions for this oncology biologic.

TEVIMBRA (TISLELIZUMAB-JSGR) — BEIGENE, SUPPLEMENTAL APPROVAL

  • BeiGene received a supplemental approval for TEVIMBRA (tislelizumab-jsgr), a PD-1 checkpoint inhibitor; supplemental approvals in this drug class generally reflect new tumor-type indications.

TIVICAY / TIVICAY PD (DOLUTEGRAVIR SODIUM) — VIIV HEALTHCARE, SUPPLEMENTAL APPROVALS

  • ViiV Healthcare received supplemental approvals on both its adult formulation TIVICAY and pediatric formulation TIVICAY PD (dolutegravir sodium), an integrase strand transfer inhibitor used in HIV treatment and prevention.

ZEPBOUND (TIRZEPATIDE) — ELI LILLY AND CO., SUPPLEMENTAL APPROVAL

  • Eli Lilly received a supplemental approval for ZEPBOUND (tirzepatide), the dual GIP/GLP-1 receptor agonist originally approved for obesity; supplemental actions may reflect new dosing, indications, or labeling updates.

🧪 CLINICAL TRIALS

ARGENTINIAN TANGO FOR COGNITIVE-MOTOR AGING (NCT07800494)

  • A new randomized controlled trial registered September 2, 2026, will enroll 270 adults aged 55 to 60 years to determine whether the frequency of adapted Argentine tango training sessions (with total weekly minutes held constant) differentially improves dual-task walking — walking while simultaneously performing a cognitive task — an important functional marker of healthy aging.

TELE-REHABILITATION VS. ON-SITE REHABILITATION FOR OLDER ADULTS WITH KNEE OSTEOARTHRITIS (NCT07798973)

  • A randomized controlled trial registered September 2, 2026, targets geriatric patients with knee osteoarthritis (KOA) to compare telerehabilitation with in-person physiotherapy on balance, mobility, and fall risk — addressing a high-burden condition in aging populations and the growing importance of remote care delivery.

VOLUNTEERING-IN-PLACE FOR APATHY IN ASSISTED LIVING RESIDENTS WITH ADRD (NCT06735950)

  • A trial registered September 2, 2026, tests two behavioral interventions targeting apathy — a highly prevalent but undertreated neuropsychiatric symptom — in assisted living residents with Alzheimer's disease and related dementias (ADRD), aiming to reduce functional decline through meaningful social engagement.

DIGITAL STORYTELLING TO REDUCE FALLS IN COMMUNITY-DWELLING OLDER ADULTS (NCT07628816)

  • A study registered September 2, 2026, evaluates whether a digital storytelling program based on Pender's Health Promotion Model can reduce fall incidence, fear of falling, and improve self-efficacy in home-dwelling older adults — addressing one of the top causes of injury-related death in people over 65.

TSLPR-TARGETED CAR-T FOR CRLF2-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (NCT07572136)

  • A trial registered September 2, 2026, is testing anti-CRLF2-R/TSLPR chimeric antigen receptor T cells (TSLPR-CART) in participants with recurrent or refractory CRLF2-rearranged B-ALL, a genetically defined high-risk leukemia subtype where excess TSLPR protein on cancer cells is the therapeutic target.

VEPDEGESTRANT (ARV-471) IN ADVANCED BREAST CANCER — TACTIVE-U SUB-STUDY A (NCT05548127)

  • This ongoing study, with an activity update September 2, 2026, continues to evaluate vepdegestrant (a PROTAC estrogen receptor degrader) in combination with other agents for advanced or metastatic estrogen receptor-positive breast cancer — a cancer type relevant to post-menopausal women and thus intersecting aging biology and oncology.

INHALED AZACYTIDINE PLUS DURVALUMAB IN EARLY-STAGE NSCLC — AZA-AEGEAN (NCT06694454)

  • An epigenetic-immunotherapy neoadjuvant trial registered September 2, 2026, tests inhaled azacytidine (a DNA methyltransferase inhibitor) combined with durvalumab (MEDI4736, a PD-L1 blocker) and platinum-based chemotherapy before surgery in operable early-stage non-small cell lung cancer — addressing the fact that most post-surgical recurrences remain untreated at the epigenetic level.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA: SHARP RISE REPORTED BY CDC

  • A CDC report released September 23, 2025, found a dramatic increase in dangerous drug-resistant bacteria in the United States, underscoring that antimicrobial resistance (AMR) remains an escalating threat to patients across all care settings.

CONGENITAL SYPHILIS: 12TH CONSECUTIVE YEAR OF INCREASE

  • New CDC data released September 24, 2025, showed U.S. cases of syphilis in newborns rose for the 12th consecutive year in 2024, signaling that maternal screening and treatment gaps continue to drive preventable infant harm.

LISTERIA OUTBREAKS: ONGOING ALERTS ON MULTIPLE PREPARED FOODS

  • As of late September 2025, CDC expanded its Listeria outbreak alert to include additional prepared meals beyond the originally recalled products, with 3 new illnesses and 1 additional death reported.
  • CDC continued urging consumers to check refrigerators and freezers for recalled foods as of October 30, 2025, noting that illnesses persisted despite ongoing product recalls.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste as malaria-free on July 23, 2025, crediting a nation-wide response launched shortly after independence in 2002 — a landmark public health achievement demonstrating that elimination is achievable in low-resource settings.

U.S. WITHDRAWAL FROM WHO NOW COMPLETE

  • The United States completed its formal withdrawal from the World Health Organization on January 22, 2026; WHO stated the decision makes both the U.S. and the world less safe.

KINDERGARTEN VACCINATION RATES: HIGH BUT SLIGHTLY DECLINING

  • CDC data released August 17, 2026, showed kindergarten vaccination coverage remains high nationally, but dropped 0.1 percentage points — a small but directionally concerning trend given recent measles resurgence.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Engineered senescence-targeting apoptotic extracellular vesicl… — Europe PMC — Longevity
  3. Dual-modal antioxidant and epigenetic synergy attenuates the s… — Europe PMC — Longevity
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260903-02-v64 · 2026-09-03 02:01 UTC · pulse.uzylab.com

Read next